TRACON Pharmaceuticals, Inc. Announces Executive Changes
September 20, 2019 at 04:12 pm
Share
On September 18, 2019, the board of directors of TRACON Pharmaceuticals, Inc. appointed Scott Brown as the Company’s Chief Accounting Officer. Mr. Brown was also designated as the Company’s principal accounting officer, replacing Charles Theuer in that role. Mr. Brown, age 39, joined the Company as Director, Finance and Controller in August 2015, was promoted to Sr. Director, Finance and Controller in January 2017, and was promoted to Vice President, Finance and Head of Finance in January 2019. Prior to joining the Company, Mr. Brown was Associate Director, Finance at Ardea Biosciences (acquired by AstraZeneca) where he led finance and accounting for Ardea Biosciences as a subsidiary of AstraZeneca from 2013 to 2015.
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
TRACON PHARMACEUTICALS, INC. 
